VSTM - Verastem, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.73
+0.40 (+7.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.33
Open5.36
Bid0.00 x 45900
Ask0.00 x 1300
Day's Range5.35 - 5.80
52 Week Range1.92 - 5.80
Volume2,507,482
Avg. Volume1,100,869
Market Cap372.938M
Beta3.41
PE Ratio (TTM)N/A
EPS (TTM)-1.76
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.67
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Verastem Oncology Announces Closing of Underwriter’s Option to Purchase Additional Shares

    Verastem, Inc., (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has issued 1,166,666 shares of the Company’s common stock at a price to the public of $4.50 per share, pursuant to the full exercise of the underwriter’s option to purchase additional shares of common stock in connection with the Company’s previously announced public offering. The aggregate gross proceeds to Verastem Oncology from the offering, including the full exercise of the underwriter’s option, are expected to be $40.2 million.

  • Business Wire3 days ago

    Verastem Oncology to Present Scientific Data Supporting Immuno-Oncology Applications of Duvelisib & Defactinib at the 3rd Annual Advances in Immuno-Oncology Congress

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that Jonathan Pachter, PhD, the Company’s Chief Scientific Officer, will give an oral presentation and moderate a roundtable discussion at the 3rd Annual Advances in Immuno-Oncology Congress being held May 24-25, 2018 in London, UK.

  • Business Wire8 days ago

    Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting

    Verastem Oncology , a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the selection of four abstracts for oral and poster presentations at the 23rd Congress of the European Hematology Association being held June 14-17, 2018 in Stockholm, Sweden.

  • Business Wire8 days ago

    Verastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that five abstracts have been selected for poster presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 1-5, 2018 in Chicago. The Company will present data on its lead product candidate, duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, as well as defactinib, its oral small molecule inhibitor of Focal Adhesion Kinase (FAK). The poster presentations will highlight the latest findings from the Company’s ongoing clinical trials for duvelisib, the Phase 3 DUO study crossover extension in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), in addition to a Phase 1 study of defactinib in combination with pembrolizumab and gemcitabine in patients with relapsed/refractory pancreatic cancer.

  • Why Verastem Stock Is Plunging Today
    Motley Fool9 days ago

    Why Verastem Stock Is Plunging Today

    The biotech is raising cash ahead of a potential launch of its first drug.

  • Business Wire9 days ago

    Verastem Oncology Announces Pricing of Public Offering of Common Stock

    Verastem, Inc., (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its registered underwritten public offering of 7,777,778 shares of its common stock at a price to the public of $4.50 per share. The gross proceeds to Verastem Oncology from the offering are expected to be $35 million. In addition, Verastem Oncology has granted the underwriter a 30-day option to purchase up to an additional 1,166,666 shares of its common stock.

  • Benzinga9 days ago

    Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 15) Inspire Medical Systems Inc (NYSE: INSP ) Aptevo Therapeutics ...

  • Business Wire9 days ago

    Verastem Oncology Announces Public Offering of Common Stock

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has commenced a registered underwritten public offering of $35 million of its shares of common stock. In addition, Verastem Oncology has granted the underwriter a 30-day option to purchase up to an additional $5.25 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Verastem Oncology.

  • Business Wire20 days ago

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to ten new employees to purchase an aggregate of 209,000 shares of Verastem Oncology’s common stock. The options were granted as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $4.19, the closing price of Verastem's common stock as reported by Nasdaq on May 1, 2018.

  • Associated Press21 days ago

    Verastem: 1Q Earnings Snapshot

    The Needham, Massachusetts-based company said it had a loss of 41 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Business Wire21 days ago

    Verastem Oncology Reports First Quarter 2018 Financial Results

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the quarter ended March 31, 2018 and provided an overview of certain corporate developments.

  • Business Wire22 days ago

    Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, yes

  • Boston biotech entrepreneur Christoph Westphal launches new startup
    American City Business Journals23 days ago

    Boston biotech entrepreneur Christoph Westphal launches new startup

    Westphal has a long track record of co-founding successful drug developers, including Alnylam Pharmaceuticals and Momenta Pharmaceuticals.

  • Business Wirelast month

    Verastem to Host Analyst and Investor Day on May 2, 2018

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it will host an Analyst and Investor Day titled, “Duvelisib: Harnessing the Power of Dual PI3K Inhibition,” on Wednesday, May 2, 2018 from 10:30 am – 1:00 pm ET in New York City.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Verastem (VSTM) in Focus: Stock Moves 8% Higher
    Zackslast month

    Verastem (VSTM) in Focus: Stock Moves 8% Higher

    Shares of Verastem (VSTM) rose nearly 8% yesterday.

  • Business Wirelast month

    Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an aggregate of 364,000 shares of Verastem’s common stock.

  • CNBC2 months ago

    Biotech shares soar on dealmaking, drug breakthroughs; AveXis jumps 77 percent

    AveXis shares led the biotech sector higher on Monday after Novartis announced its plans to buy the gene therapy company.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Verastem Inc (NASDAQ: VSTM ) stock gained more than ...

  • Business Wire2 months ago

    FDA Accepts New Drug Application for Duvelisib and Grants Priority Review

    Verastem, Inc. , a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S.

  • Business Wire2 months ago

    Verastem to Present at the H.C. Wainwright Global Life Sciences Conference

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C.

  • Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
    Zacks2 months ago

    Infinity (INFI) Reports Narrower-than-Expected Loss in Q4

    Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.

  • Business Wire2 months ago

    Verastem Updates Presentation Time for Oppenheimer & Co. Healthcare Conference

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 28th Annual Oppenheimer & Co.

  • Business Wire2 months ago

    Verastem to Present at Upcoming Conferences

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will

  • Business Wire2 months ago

    Verastem Reports Year-End 2017 Financial Results

    Verastem, Inc. , focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the year ended December 31, 2017 and provided an overview of certain corporate developments and plans.